2016 03 10 Next Generation Sequencing for cancer testing available at the National Center of Pathology

tituline-72d945a38a610a7662792269324b13c0.jpg

The National Center of Pathology has implemented genetic cancer profiling based on Next Generation Sequencing (NGS). This technology is becoming a gold-standard in cancer tissue testing for personalized medicine. Cancer therapy choices are increasingly based on genetic profiling of tumor tissue to predicting potential outcomes and responses of the disease. 

CE-IVD certified ThermoFisher Scientific Inc. system for NGS is implemented to enable comprehensive testing of over 1,600 hotspot mutations in 22 genes related to cancer progression: EGFR, ALK, ERBB2, ERBB4, FGFR1, FGFR2, FGFR3, MET, DDR2, KRAS, PIK3CA, BRAF, AKT1, PTEN, NRAS, MAP2K1, STK11, NOTCH1, CTNNB1, SMAD4, FBXW7, TP53. The test is primarily informative for lung cancer since it detects the majority of clinically relevant mutations published.  Furthermore, patients with colorectal and other cancers will benefit from the new testing modalities. 

Molecular and Digital Pathology Laboratory at the National Center of Pathology also provides techniques based on multiplex polymerase chain reaction (HPV, STD) and real-time PCR (KRAS, NRAS, BRAF, EGFR), performed on FFPE specimens, as well as using “liquid biopsy” samples. The Laboratory also provides molecular/digital pathology testing and research services in close cooperation of the team of pathologists, pathology informatics, bioinformatics, geneticists, serving as an open access center at the Santara Valley.